Clinical outcomes: entire cohort
| Outcomes | EVT (n=184) | No EVT (n=188) | Crude OR (95% CI) | P values | Adjusted OR (95% CI) | P values |
| Primary outcome | ||||||
| mRS score 0–2 at 90 days, n (%) | 105 (57.1) | 95 (50.5) | 1.30 (0.86 to 1.95) | 0.21 | 2.09 (1.26 to 3.47) | 0.004 |
| Secondary outcomes | ||||||
| mRS score 0–1 at 90 days, n (%) | 66 (35.9) | 66 (35.1) | 1.03 (0.67 to 1.58) | 0.91 | 1.53 (0.92 to 2.55) | 0.09 |
| Mortality at 90 days, n (%) | 7 (3.8) | 11 (5.9) | 0.63 (0.24 to 1.67) | 0.47 | 0.27 (0.08 to 0.93) | 0.03 |
| Safety outcomes | ||||||
| Intracranial hemorrhage within 72 hours, n (%) | 51 (27.7) | 41 (21.8) | 1.25 (0.77 to 2.01) | 0.39 | 1.17 (0.68 to 2.00) | 0.55 |
| Symptomatic intracranial hemorrhage within 72 hours, n (%) | 7 (3.8) | 7 (3.7) | 0.94 (0.32 to 2.76) | 0.99 | 1.38 (0.42 to 4.47) | 0.59 |
EVT, endovascular therapy; mRS, modified Rankin Scale.